BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 22465695)

  • 21. Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods.
    Zwaenepoel K; Van Dongen A; Lambin S; Weyn C; Pauwels P
    Histopathology; 2014 Oct; 65(4):539-48. PubMed ID: 24621075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.
    Lung J; Lin YC; Hung MS; Jiang YY; Lee KD; Lin PY; Tsai YH
    Lung Cancer; 2016 Apr; 94():114-20. PubMed ID: 26973216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical screening and fluorescence in situ hybridization confirmation of ALK translocation in lung adenocarcinoma and its clinicopathological significance: a single-center large-scale investigation of Chinese patients.
    Wang WY; Liang DN; Yao WQ; Wu WL; Li JN; Chen M; Liao DY; Zhang M; Li GD
    Hum Pathol; 2014 Jul; 45(7):1414-22. PubMed ID: 24775606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
    Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
    J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
    Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
    Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer.
    Houang M; Toon CW; Clarkson A; Sioson L; Watson N; Farzin M; Selinger CI; Chou A; Morey AL; Cooper WA; O'Toole SA; Gill AJ
    Pathology; 2014 Aug; 46(5):383-8. PubMed ID: 24842379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
    Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
    Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
    Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
    J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
    Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
    J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
    von Laffert M; Warth A; Penzel R; Schirmacher P; Kerr KM; Elmberger G; Schildhaus HU; Büttner R; Lopez-Rios F; Reu S; Kirchner T; Pauwels P; Specht K; Drecoll E; Höfler H; Aust D; Baretton G; Bubendorf L; Stallmann S; Fisseler-Eckhoff A; Soltermann A; Tischler V; Moch H; Penault-Llorca F; Hager H; Schäper F; Lenze D; Hummel M; Dietel M
    J Thorac Oncol; 2014 Nov; 9(11):1685-92. PubMed ID: 25436802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).
    Kotoula V; Bobos M; Vassilakopoulou M; Tsolaki E; Chrisafi S; Psyrri A; Lazaridis G; Papadopoulou K; Efstratiou I; Michail-Strantzia C; Debelenko LV; Kosmidis P; Fountzilas G
    Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):60-70. PubMed ID: 25153496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.
    Savic S; Diebold J; Zimmermann AK; Jochum W; Baschiera B; Grieshaber S; Tornillo L; Bisig B; Kerr K; Bubendorf L
    Lung Cancer; 2015 Aug; 89(2):104-9. PubMed ID: 26056079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
    Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
    Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
    Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
    Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches.
    Demidova I; Grinevich V; Avdalian A; Imyanitov E; Gikalo M; Savelov N; Novikova I; Samuilenkova O; Tiurin V; Ulianova E; Tsimafeyeu I; Tjulandin S
    Lung Cancer; 2017 Jan; 103():17-23. PubMed ID: 28024691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
    Tuononen K; Kero M; Mäki-Nevala S; Sarhadi VK; Tikkanen M; Wirtanen T; Rönty M; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2014 Nov; 53(11):895-901. PubMed ID: 24942490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
    J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.